Zacks Research Comments on Corcept Therapeutics Incorporated’s Q1 2025 Earnings (NASDAQ:CORT)

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Analysts at Zacks Research increased their Q1 2025 earnings per share (EPS) estimates for Corcept Therapeutics in a research note issued on Tuesday, October 1st. Zacks Research analyst K. Das now forecasts that the biotechnology company will earn $0.30 per share for the quarter, up from their previous forecast of $0.29. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.12 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q2 2025 earnings at $0.33 EPS, Q3 2025 earnings at $0.39 EPS, Q4 2025 earnings at $0.48 EPS, FY2025 earnings at $1.50 EPS and FY2026 earnings at $2.15 EPS.

Several other research firms have also issued reports on CORT. Truist Financial raised their price target on Corcept Therapeutics from $65.00 to $76.00 and gave the stock a “buy” rating in a research report on Monday, September 30th. Piper Sandler raised their target price on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 18th. HC Wainwright raised their target price on shares of Corcept Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, July 30th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $38.00 target price on shares of Corcept Therapeutics in a report on Tuesday, July 30th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $56.50.

Corcept Therapeutics Stock Up 0.9 %

NASDAQ CORT opened at $45.43 on Thursday. The stock’s 50-day simple moving average is $37.50 and its two-hundred day simple moving average is $31.44. Corcept Therapeutics has a twelve month low of $20.84 and a twelve month high of $47.71. The company has a market capitalization of $4.73 billion, a price-to-earnings ratio of 42.86 and a beta of 0.45.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Monday, July 29th. The biotechnology company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.09. Corcept Therapeutics had a return on equity of 23.66% and a net margin of 21.93%. The business had revenue of $163.80 million during the quarter, compared to analyst estimates of $155.14 million. During the same period in the prior year, the company earned $0.25 earnings per share. Corcept Therapeutics’s revenue was up 39.1% compared to the same quarter last year.

Insider Activity at Corcept Therapeutics

In other Corcept Therapeutics news, insider Gary Charles Robb sold 11,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $46.28, for a total value of $509,080.00. Following the sale, the insider now owns 22,772 shares in the company, valued at $1,053,888.16. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Gary Charles Robb sold 11,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $46.28, for a total transaction of $509,080.00. Following the transaction, the insider now directly owns 22,772 shares in the company, valued at approximately $1,053,888.16. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider William Guyer sold 10,000 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $35.30, for a total transaction of $353,000.00. Following the transaction, the insider now owns 6,039 shares in the company, valued at $213,176.70. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 34,251 shares of company stock worth $1,365,292. 20.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets lifted its stake in Corcept Therapeutics by 199.0% during the 1st quarter. BNP Paribas Financial Markets now owns 211,592 shares of the biotechnology company’s stock valued at $5,330,000 after acquiring an additional 140,815 shares during the period. Quantedge Capital Pte Ltd purchased a new stake in Corcept Therapeutics in the 4th quarter worth $8,066,000. Oak Ridge Investments LLC purchased a new stake in Corcept Therapeutics in the 2nd quarter worth $984,000. State Board of Administration of Florida Retirement System grew its holdings in shares of Corcept Therapeutics by 190.0% during the first quarter. State Board of Administration of Florida Retirement System now owns 66,866 shares of the biotechnology company’s stock worth $1,684,000 after buying an additional 43,809 shares in the last quarter. Finally, US Bancorp DE grew its holdings in shares of Corcept Therapeutics by 6,252.3% during the first quarter. US Bancorp DE now owns 25,282 shares of the biotechnology company’s stock worth $637,000 after buying an additional 24,884 shares in the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.